News
-
-
-
-
PRESS RELEASE
Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting
Napo Pharmaceuticals announced the acceptance of an abstract on crofelemer powder study for SBS-IF at ACG 2026. Napo focuses on global crofelemer development for rare IF diseases -
-
PRESS RELEASE
Jaguar Health Receives Fee Waivers from FDA
Napo Pharmaceuticals and Jaguar Health receive waivers from FDA for Mytesi and Canalevia fees for 2027. Jaguar develops GI drugs from plants; focus on rare disorders and mental health. For safety information, visit Mytesi.com and Canalevia.com -
-
-
-
PRESS RELEASE
All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Napo Pharmaceuticals enters extension phase with blinded doses of crofelemer to support NDA filing for ultrarare pediatric disease MVID in mid-2027
